Literature DB >> 18587585

[Legal regulations to produce serum eye drops : when is it necessary, and how can it be obtained?].

G Geerling1, F Grus, B Seitz, D Hartwig, F Schirra.   

Abstract

According to European Union and German legislation, the production of medicines such as eye drops from autologous serum requires a license from an appropriate authority. However, an exemption is granted to medical doctors who produce and apply medications under their immediate responsibility. If doctors do not actually produce such medications themselves, they must select appropriate personnel to do so. These individuals have to be sufficiently qualified and reliable and must be carefully instructed on the standard quality and manufacturing procedures, although the doctors are responsible for controlling the production and quality of the final product. The treating physicians are also responsible for the appropriate application of the produced medications. To dispense medication to patients without an appropriate license is considered a criminal offense. We describe how two German hospitals have established the production of serum eye drops in full compliance with legal regulations.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18587585     DOI: 10.1007/s00347-008-1751-x

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  4 in total

1.  [Chemical and thermal eye burns. Conservatíve and surgical options of a stage-dependent therapy].

Authors:  H G Struck; N F Schrage
Journal:  Ophthalmologe       Date:  2011-10       Impact factor: 1.059

2.  [Introduction to the topic: blood products for treatment of diseases of the ocular surface. Voodoo or standard therapy].

Authors:  G Geerling; B Seitz
Journal:  Ophthalmologe       Date:  2008-07       Impact factor: 1.059

Review 3.  [Albumin eye drops for treatment of ocular surface diseases].

Authors:  J D Unterlauft; M Kohlhaas; I Hofbauer; K Kasper; G Geerling
Journal:  Ophthalmologe       Date:  2009-10       Impact factor: 1.059

Review 4.  [Autologous serum and alternative blood products for the treatment of ocular surface disorders].

Authors:  G Geerling; J D Unterlauft; K Kasper; S Schrader; A Opitz; D Hartwig
Journal:  Ophthalmologe       Date:  2008-07       Impact factor: 1.059

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.